Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion

DRUG4 trials

Sponsors

Prinses Maxima Centrum voor Kinderoncologie B.V., University College Dublin, Kite Pharma Inc., Cancer Trials Ireland

Conditions

Advanced Hepatocellular Carcinoma (HCC)Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or LessNeuroblastomaPatients with 1-3 positive NodesRelapsed/Refractory Follicular Lymphoma

Phase 1

Phase Ib study combining dinutuximab beta with induction chemotherapy regimens in patients with newly diagnosed high-risk neuroblastoma: SIOPEN-Pilot01

RecruitingCTIS2023-509673-22-00

Prinses Maxima Centrum voor Kinderoncologie B.V.Neuroblastoma

Start: 2024-12-02Target: 39Updated: 2025-09-11

Phase 2

A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)

CompletedCTIS2023-510117-26-00

University College DublinAdvanced Hepatocellular Carcinoma (HCC)

End: 2025-05-06Target: 29Updated: 2025-03-31

Phase 3

A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma

Active, not recruitingCTIS2024-511594-30-00

Kite Pharma Inc.Relapsed/Refractory Follicular Lymphoma

Start: 2023-02-23Target: 142Updated: 2026-01-14

SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive Nodes Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less

Active, not recruitingCTIS2024-516801-22-00

Cancer Trials IrelandHormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less, Patients with 1-3 positive Nodes

Start: 2012-04-26Target: 141Updated: 2025-05-20